期刊
ONCOGENE
卷 39, 期 18, 页码 3620-3637出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41388-020-1249-9
关键词
-
资金
- Wellcome Trust Strategic Fund [PS3416]
- Cancer Research UK [C57701/A26137]
- Wellcome Trust
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据